Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ASMB
SellSinkerAssembly Biosciences, Inc. · Healthcare · United States · $694M · Avg Vol: $9M/d
COMPANY DESCRIPTION
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing new oral therapeutics for serious viral diseases, with a primary focus on chronic Hepatitis B virus (HBV) infection. The company leverages its proprietary core inhibitor pipeline to address a significant global health challenge. It operates as a specialized biotech firm dedicated to innovative antiviral drug discovery.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.3M | 0 | 7.2M | 28.5M | 72.3M | 84.4% | 74.8M | 63.4M | 34.4M | -31.0% |
| EPS | -36.00 | -4.74 | -3.70 | -2.52 | -0.55 | — | 1.24 | 0.14 | -2.11 | — |
| Shares | 4.0M | 19.8M | 19.8M | 19.8M | 15.9M | +295.4% | 20.4M | — | — | — |
| Debt | 6.5M | 3.5M | 2.3M | 3.1M | 2.6M | -20.2% | 2.4M | — | — | — |
| Equity | 168.9M | 82.7M | 41.1M | 33.4M | 206.8M | 5.2% | — | — | — | — |
| Op CF | -93.4M | -84.5M | 22.7M | -51.1M | -41.1M | — | -38.5M | — | — | — |
| Inv CF | 26.5M | 90.6M | -69.1M | 40.2M | -113.5M | — | — | — | — | — |
| Fin CF | 53.1M | 0.6M | 13.8M | 29.4M | 174.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ASMB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ASMB | Assembly Biosciences, Inc.(you) | $694M | 31 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| GYRE | Gyre Therapeutics, Inc. | $699M | 34 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| FTH | Faeth Therapeutics, Inc. | $874M | 30 | Sell |
| VSTM | Verastem, Inc. | $654M | 27 | Sell |
| DRUG.CN | Bright Minds Biosciences Inc. | $698M | 24 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 29 | Sell |
| OVID | Ovid Therapeutics Inc. | $547M | 35 | Sell |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.3%